Immunwork Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Jan 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Pharmaceuticals in joint-linker configurations for treating pathological blood clots (US 10,383,947) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Molecular constructs with targeting and effector moieties for treating infectious diseases (US 10,442,861) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Composite polypeptide having a metal binding motif and molecular construct comprising the same (US 11,926,678) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,623,118 | Multi-arm linker constructs for treating pathological blood clots In force · From the USPTO record | In force | From the USPTO record | |
| US 9,975,951 | Peptide core-based multi-arm linkers and their applications In force · From the USPTO record | In force | From the USPTO record | |
| US 9,988,454 | Peptide core-based multi-arm linkers for treating central nervous system diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 10,202,455 | Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod In force · From the USPTO record | In force | From the USPTO record | |
| US 10,442,861 | Molecular constructs with targeting and effector moieties for treating infectious diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,994,638 | Peptide core-based multi-arm linkers for treating infectious diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,907,858 | Peptide core-based multi-arm linkers In force · Medium confidence | In force | Medium confidence | |
| US 10,010,626 | Molecular constructs with targeting and effector moieties In force · Medium confidence | In force | Medium confidence | |
| US 10,383,947 | Pharmaceuticals in joint-linker configurations for treating pathological blood clots In force · From the USPTO record | In force | From the USPTO record | |
| US 10,300,104 | Multi-Arm Linker for Treating Rejection Reaction in Transplantation In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 18: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 7 no status recorded